

REMARKS

The claims have been amended above to clarify the nature of the claimed invention. Specifically, claim 49 has been amended to indicate that the claimed composition may comprise at least one anthrax antigen, and that the at least one anthrax antigen and the at least one mucosal adjuvant are in combination with a mucosal administration device. Dependent claims 50-54 have been amended to preserve antecedent basis with amended claim 49. Support for the new claims may be found throughout the specification of the PCT application as filed, for instance in original claim 1, and in paragraph 097. No prohibited new matter has been added by way of this amendment.


If the Examiner has any further questions relating to this Amendment or to the application in general, he or she is respectfully requested to contact the undersigned by telephone so that allowance of the present application may be expedited.

Dated: April 17, 2007

COOLEY GODWARD KRONISH LLP
ATTN: Patent Group
1200 19th Street, NW, 5th Floor
Washington, DC 20036
Tel: (202) 842-7800
Fax: (202) 842-7899

Respectfully submitted,
COOLEY GODWARD KRONISH LLP

By:



Bonnie Weiss McLeod
Reg. No. 43,255